Roche paves way for a new era of HCC treatment
Bangkok, Thailand – Roche, the world’s largest biotech company and a global pioneer in pharmaceuticals and diagnostics, led by Farid Bidgoli (3rd from right), General Manager, Roche Thailand, Myanmar, Cambodia and Laos, along with Saranond Assavavipapan (Left), Integrated Disease Value Lead, Kultida Leenabanchong (2nd from left), Communications Lead, Deepti Saraf (3rd from left), Integrated Disease Value Lead, Morris Chiko (right), Finance and Operations Value Lead and Sansanee Lerdlitruangsin, MD. (2nd from right), Integrated Medical Value Lead, hosted the ‘HCC Enters a New Era of Treatment’ seminar. The event brought attention to liver cancer, as the number one cancer killer in Thai men, with exchange of knowledge in new treatment approaches, Thailand specific hepatocellular carcinoma (HCC) research, as well as early experience case discussion in unresectable HCC. The event was joined by close to 100 medical professionals and industry experts at Centara Grand at CentralWorld, recently.